Custom Search


Friday 01 October 2004

Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.

By: Gajra A, Vajpayee N, Grethlein SJ.

Am J Hematol 2004 Oct;77(2):196-7

Myasthenia gravis is a B-cell-mediated autoimmune neuromuscular disorder characterized by weakness and fatigability of skeletal muscles. The underlying defect is an autoantibody-mediated attack on the acetylcholine receptors (AchRs) at the neuromuscular junction. Rituximab is a genetically engineered chimeric murine/human monoclonal antibody indicated for treatment of patients with low-grade or follicular, CD20-positive, B-cell non-Hodgkin lymphoma. Based on its potential for elimination of auto-reactive B-cell clones, rituximab may have a role in the management of some autoimmune disorders. We report a patient with B-cell, follicular non-Hodgkin lymphoma and a long-standing history of myasthenia gravis and the favorable impact of rituximab on both disorders. Copyright 2004 Wiley-Liss, Inc.

Use of this site is subject to the following terms of use